

Jean-Yves Reginster

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/617686/jean-yves-reginster-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

336
papers

27,489
citations

69
h-index

161
g-index

360
ext. papers

33,592
ext. citations

5.3
avg, IF

7
L-index

#	Paper	IF	Citations
336	Neurofilament light chain concentration in an aging population.. <i>Aging Clinical and Experimental Research</i> , 2022 , 34, 331	4.8	1
335	Attributes and definitions of locomotor capacity in older people: a World Health Organisation (WHO) locomotor capacity working group meeting report.. <i>Aging Clinical and Experimental Research</i> , 2022 , 34, 481	4.8	0
334	Osteoporosis: burden, diagnosis, and management 2022 , 972-978		
333	Management of patients at very high risk of osteoporotic fractures through sequential treatments.. <i>Aging Clinical and Experimental Research</i> , 2022 , 1	4.8	4
332	The current situation in the approach to osteoporosis in older adults in Turkey: areas in need of improvement with a model for other populations. <i>Archives of Osteoporosis</i> , 2021 , 16, 179	2.9	0
331	Frailty but not sarcopenia nor malnutrition increases the risk of developing COVID-19 in older community-dwelling adults. <i>Aging Clinical and Experimental Research</i> , 2021 , 1	4.8	2
330	Fracture Risk Assessment and How to Implement a Fracture Liaison Service. <i>Practical Issues in Geriatrics</i> , 2021 , 241-256	0.1	2
329	Experts' preferences for sarcopenia outcomes: a discrete-choice experiment from a working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) in collaboration with the European Union of Geriatric Medicine Society (EUGMS). <i>Aging Clinical and Experimental Research</i> , 2021 , 33, 1079-1083	4.8	1
328	P113 How has COVID-19 affected the treatment of osteoporosis? The answers from a global survey. <i>Rheumatology</i> , 2021 , 60,	3.9	78
327	Cost-Effectiveness Assessment of Different Glucosamines in Patients with Knee Osteoarthritis: A Simulation Model Adapted to Germany. <i>Current Aging Science</i> , 2021 , 14, 242-248	2.2	1
326	Quality of Life and Sarcopenia 2021 , 279-304		0
325	Malnutrition, assessed by the Global Leadership Initiative on Malnutrition (GLIM) criteria but not by the mini nutritional assessment (MNA), predicts the incidence of sarcopenia over a 5-year in the SarcoPhAge cohort. <i>Aging Clinical and Experimental Research</i> , 2021 , 33, 1507-1517	4.8	4
324	Identifying maternal needs following childbirth: comparison between pregnant women and recent mothers. <i>BMC Pregnancy and Childbirth</i> , 2021 , 21, 405	3.2	2
323	2021 revised algorithm for the management of knee osteoarthritis-the Chinese viewpoint. <i>Aging Clinical and Experimental Research</i> , 2021 , 33, 2141-2147	4.8	2
322	Orthogeriatrics: a vital requirement for improving fragility fracture patient care internationally with particular reference to Turkey. <i>Archives of Osteoporosis</i> , 2021 , 16, 103	2.9	1
321	Assessment of the performance of the SarQoL questionnaire in screening for sarcopenia in older people. <i>Aging Clinical and Experimental Research</i> , 2021 , 33, 2149-2155	4.8	1
320	Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults. <i>Aging Clinical and Experimental Research</i> , 2021 , 33, 3-17	4.8	16

319	Highly purified chondroitin sulfate: a literature review on clinical efficacy and pharmacoeconomic aspects in osteoarthritis treatment. <i>Aging Clinical and Experimental Research</i> , 2021 , 33, 37-47	4.8	16
318	An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis. <i>Pharmacoeconomics</i> , 2021 , 39, 181-209	4.4	25
317	Prediction of 5-year mortality risk by malnutrition according to the GLIM format using seven pragmatic approaches to define the criterion of loss of muscle mass. <i>Clinical Nutrition</i> , 2021 , 40, 2188-2199	5.9	4
316	Impact of Malnutrition Status on Muscle Parameter Changes over a 5-Year Follow-Up of Community-Dwelling Older Adults from the SarcoPhAge Cohort. <i>Nutrients</i> , 2021 , 13,	6.7	4
315	The presence of erosive joints is a strong predictor of radiological progression in hand osteoarthritis: results of a 2-year prospective follow-up of the Liège Hand Osteoarthritis Cohort (LIHOC). <i>Arthritis Research and Therapy</i> , 2021 , 23, 12	5.7	2
314	Evaluating quality of life in frailty: applicability and clinimetric properties of the SarQoL questionnaire. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021 , 12, 319-330	10.3	4
313	2019 revised algorithm for the management of knee osteoarthritis: the Southeast Asian viewpoint. <i>Aging Clinical and Experimental Research</i> , 2021 , 33, 1149-1156	4.8	2
312	A Combination of Celecoxib and Glucosamine Sulfate Has Anti-Inflammatory and Chondroprotective Effects: Results from an In Vitro Study on Human Osteoarthritic Chondrocytes. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	4
311	Knee Osteoarthritis Pain Management with an Innovative High and Low Molecular Weight Hyaluronic Acid Formulation (HA-HL): A Randomized Clinical Trial. <i>Rheumatology and Therapy</i> , 2021 , 8, 1617-1636	4.4	4
310	Patients' preferences for quality-of-life aspects in sarcopenia: a best-worst scaling study. <i>European Geriatric Medicine</i> , 2021 , 1	3	
309	Lower Limb Muscle Strength and Muscle Mass Are Associated With Incident Symptomatic Knee Osteoarthritis: A Longitudinal Cohort Study.. <i>Frontiers in Endocrinology</i> , 2021 , 12, 804560	5.7	3
308	The effects of GAMotion (a giant exercising board game) on physical capacity, motivation and quality of life among nursing home residents: A pilot interventional study. <i>Experimental Gerontology</i> , 2020 , 138, 110983	4.5	2
307	Motivational climate of group exercise sessions in nursing homes. <i>Archives of Public Health</i> , 2020 , 78, 43	2.6	0
306	Physical performance trajectories and mortality among nursing home residents: results of the SENIOR cohort. <i>Age and Ageing</i> , 2020 , 49, 800-806	3	4
305	Senior physical activity contests in nursing homes: a feasibility study. <i>Aging Clinical and Experimental Research</i> , 2020 , 32, 869-876	4.8	1
304	Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 394-400	5.3	9
303	The Value of a Patient-Level Modeling Approach and Need for Better Reporting in Economic Evaluations of Osteoporosis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020 , 26, 334-335	1.9	1
302	Glucosamine sulphate: an umbrella review of health outcomes. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020 , 12, 1759720X20975927	3.8	6

301	Cross-sectional Evaluation of the Sarcopenia Quality of Life (SarQoL) Questionnaire: Translation and Validation of its Psychometric Properties. <i>Annals of Geriatric Medicine and Research</i> , 2020 , 24, 139-147	2.9	2
300	Total joint replacement improves pain, functional quality of life, and health utilities in patients with late-stage knee and hip osteoarthritis for up to 5 years. <i>Clinical Rheumatology</i> , 2020 , 39, 861-871	3.9	24
299	Outcome Priorities for Older Persons With Sarcopenia. <i>Journal of the American Medical Directors Association</i> , 2020 , 21, 267-271.e2	5.9	7
298	Patient's Engagement in the Identification of Critical Outcomes in Sarcopenia. <i>Journal of the American Medical Directors Association</i> , 2020 , 21, 284-286	5.9	5
297	Prediction of Adverse Outcomes in Nursing Home Residents According to Intrinsic Capacity Proposed by the World Health Organization. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020 , 75, 1594-1599	6.4	36
296	Influence of bone mineral density in circulating adipokines among postmenopausal Arab women. <i>Saudi Journal of Biological Sciences</i> , 2020 , 27, 374-379	4	6
295	Equation models developed with bioelectric impedance analysis tools to assess muscle mass: A systematic review. <i>Clinical Nutrition ESPEN</i> , 2020 , 35, 47-62	1.3	16
294	Evaluation of a Panel of MicroRNAs that Predicts Fragility Fracture Risk: A Pilot Study. <i>Calcified Tissue International</i> , 2020 , 106, 239-247	3.9	17
293	Role of Collagen Derivatives in Osteoarthritis and Cartilage Repair: A Systematic Scoping Review With Evidence Mapping. <i>Rheumatology and Therapy</i> , 2020 , 7, 703-740	4.4	9
292	A discrete-choice experiment to assess patients' preferences for osteoarthritis treatment: An ESCEO working group. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 859-866	5.3	2
291	Mortality in malnourished older adults diagnosed by ESPEN and GLIM criteria in the SarcoPhAge study. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020 , 11, 1200-1211	10.3	28
290	Association between Changes in Nutrient Intake and Changes in Muscle Strength and Physical Performance in the SarcoPhAge Cohort. <i>Nutrients</i> , 2020 , 12,	6.7	5
289	Responder Profile to Pharmaceutical-Grade Chondroitin Sulfate: An Analysis of the CONCEPT Trial. <i>Advances in Therapy</i> , 2020 , 37, 4641-4648	4.1	0
288	Cross-cultural adaptation, translation, and validation of the functional assessment scale for acute hamstring injuries (FASH) questionnaire for French-speaking patients. <i>Disability and Rehabilitation</i> , 2020 , 42, 2076-2082	2.4	3
287	Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis. <i>Advances in Therapy</i> , 2019 , 36, 2811-2824	4.1	26
286	Sarcopenia and health-related outcomes: an umbrella review of observational studies. <i>European Geriatric Medicine</i> , 2019 , 10, 853-862	3	22
285	Sarcopenia: Performance of the SARC-F Questionnaire According to the European Consensus Criteria, EWGSOP1 and EWGSOP2. <i>Journal of the American Medical Directors Association</i> , 2019 , 20, 1182-1183	5.9	11
284	Relationship between the changes over time of bone mass and muscle health in children and adults: a systematic review and meta-analysis. <i>BMC Musculoskeletal Disorders</i> , 2019 , 20, 429	2.8	15

283	Endorsement by Central European experts of the revised ESCEO algorithm for the management of knee osteoarthritis. <i>Rheumatology International</i> , 2019 , 39, 1117-1123	3.6	11
282	Metabolic Syndrome in Arab Adults with Low Bone Mineral Density. <i>Nutrients</i> , 2019 , 11,	6.7	11
281	Validation of the Lithuanian version of sarcopenia-specific quality of life questionnaire (SarQoL). <i>European Geriatric Medicine</i> , 2019 , 10, 761-767	3	7
280	Safety of Cyclooxygenase-2 Inhibitors in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. <i>Drugs and Aging</i> , 2019 , 36, 25-44	4.7	33
279	Safety of Opioids in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. <i>Drugs and Aging</i> , 2019 , 36, 129-143	4.7	41
278	Gait symmetry in the dual task condition as a predictor of future falls among independent older adults: a 2-year longitudinal study. <i>Aging Clinical and Experimental Research</i> , 2019 , 31, 1057-1067	4.8	8
277	Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say?. <i>Drugs and Aging</i> , 2019 , 36, 15-24	4.7	74
276	Recommendations for the Reporting of Harms in Manuscripts on Clinical Trials Assessing Osteoarthritis Drugs: A Consensus Statement from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). <i>Drugs and Aging</i> , 2019 , 36, 145-159	4.7	8
275	Safety of Intra-articular Hyaluronic Acid Injections in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. <i>Drugs and Aging</i> , 2019 , 36, 101-127	4.7	35
274	Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. <i>Drugs and Aging</i> , 2019 , 36, 65-99	4.7	39
273	Safety of Topical Non-steroidal Anti-Inflammatory Drugs in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. <i>Drugs and Aging</i> , 2019 , 36, 45-64	4.7	39
272	Importance of Safety in the Management of Osteoarthritis and the Need for Updated Meta-Analyses and Recommendations for Reporting of Harms. <i>Drugs and Aging</i> , 2019 , 36, 3-6	4.7	0
271	Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review. <i>Calcified Tissue International</i> , 2019 , 105, 109-124	3.9	31
270	Practical guidance for engaging patients in health research, treatment guidelines and regulatory processes: results of an expert group meeting organized by the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). <i>Aging Clinical and Experimental Research</i> , 2019 , 31, 207-215	4.8	29
269	An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 49, 337-350	5.3	193
268	Standard error of measurement and smallest detectable change of the Sarcopenia Quality of Life (SarQoL) questionnaire: An analysis of subjects from 9 validation studies. <i>PLoS ONE</i> , 2019 , 14, e0216065	3.7	15
267	Consequences of maternal postpartum depression: A systematic review of maternal and infant outcomes. <i>Women's Health</i> , 2019 , 15, 1745506519844044	3	183
266	The effects of calorie restriction, intermittent fasting and vegetarian diets on bone health. <i>Aging Clinical and Experimental Research</i> , 2019 , 31, 753-758	4.8	17

265	Practical guidance for patient-centred health research. <i>Lancet, The</i> , 2019 , 393, 1095-1096	4.0	14
264	Efficacy of Chondroitin Sulfate in Patients with Knee Osteoarthritis: A Comprehensive Meta-Analysis Exploring Inconsistencies in Randomized, Placebo-Controlled Trials. <i>Advances in Therapy</i> , 2019 , 36, 1085-1099	4.1	26
263	Association between dietary nutrient intake and sarcopenia in the SarcoPhAge study. <i>Aging Clinical and Experimental Research</i> , 2019 , 31, 815-824	4.8	35
262	Assessment of Muscle Function and Physical Performance in Daily Clinical Practice : A position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). <i>Calcified Tissue International</i> , 2019 , 105, 1-14	3.9	156
261	Cost-effectiveness evaluation of glucosamine for osteoarthritis based on simulation of individual patient data obtained from aggregated data in published studies. <i>Aging Clinical and Experimental Research</i> , 2019 , 31, 881-887	4.8	7
260	Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 49, 184-196	5.3	15
259	Assessment of the energy expenditure of Belgian nursing home residents using indirect calorimetry. <i>Nutrition</i> , 2019 , 57, 12-16	4.8	1
258	Three-Year Adverse Health Consequences of Sarcopenia in Community-Dwelling Older Adults According to 5 Diagnosis Definitions. <i>Journal of the American Medical Directors Association</i> , 2019 , 20, 43-46.e2	5.9	25
257	Novel Approach to Estimate Osteoarthritis Progression: Use of the Reliable Change Index in the Evaluation of Joint Space Loss. <i>Arthritis Care and Research</i> , 2019 , 71, 300-307	4.7	5
256	Radiofrequency echographic multi-spectrometry for the in-vivo assessment of bone strength: state of the art-outcomes of an expert consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). <i>Aging Clinical and Experimental Research</i> , 2019 , 31, 1375-1389	4.8	27
255	East meets West: current practices and policies in the management of musculoskeletal aging. <i>Aging Clinical and Experimental Research</i> , 2019 , 31, 1351-1373	4.8	25
254	Energy Expenditure of Nursing Home Residents and Participation in Exercise Classes: An Analysis of the SENIOR Cohort. <i>Journal of the American Medical Directors Association</i> , 2019 , 20, 1183-1184	5.9	2
253	Gut microbiota and osteoarthritis management: An expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO). <i>Ageing Research Reviews</i> , 2019 , 55, 100946	12	49
252	Relationship between peak expiratory flow and incidence of frailty, deaths and falls among nursing home residents: Results of the SENIOR cohort. <i>Archives of Gerontology and Geriatrics</i> , 2019 , 85, 103913	4	7
251	Update on the role of pharmaceutical-grade chondroitin sulfate in the symptomatic management of knee osteoarthritis. <i>Aging Clinical and Experimental Research</i> , 2019 , 31, 1163-1167	4.8	16
250	Redesigning care for older people to preserve physical and mental capacity: WHO guidelines on community-level interventions in integrated care. <i>PLoS Medicine</i> , 2019 , 16, e1002948	11.6	39
249	Using supervised learning machine algorithm to identify future fallers based on gait patterns: A two-year longitudinal study. <i>Experimental Gerontology</i> , 2019 , 127, 110730	4.5	6
248	Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 899-911	18.1	61

247	Normative data for isometric strength of 8 different muscle groups and their usefulness as a predictor of loss of autonomy among physically active nursing home residents: the SENIOR cohort. <i>Journal of Musculoskeletal Neuronal Interactions</i> , 2019 , 19, 258-265	1.3	2
246	Malnutrition as a Strong Predictor of the Onset of Sarcopenia. <i>Nutrients</i> , 2019 , 11,	6.7	77
245	Mediterranean diet and knee osteoarthritis outcomes: A longitudinal cohort study. <i>Clinical Nutrition</i> , 2019 , 38, 2735-2739	5.9	20
244	The health economics burden of sarcopenia: a systematic review. <i>Maturitas</i> , 2019 , 119, 61-69	5	70
243	EWGSOP2 Versus EWGSOP1: Impact on the Prevalence of Sarcopenia and Its Major Health Consequences. <i>Journal of the American Medical Directors Association</i> , 2019 , 20, 384-385	5.9	44
242	Type 2 diabetes mellitus and osteoarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 49, 9-19	5.3	43
241	Impact du traitement par statines dans la progression radiologique de la gonarthrose : résultats issus de l'analyse post-hoc de l'essai SEKOIA. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2019 , 86, 81-86	0.1	
240	Sarcopenia: revised European consensus on definition and diagnosis. <i>Age and Ageing</i> , 2019 , 48, 16-31	3	3263
239	A new decision tree for diagnosis of osteoarthritis in primary care: international consensus of experts. <i>Aging Clinical and Experimental Research</i> , 2019 , 31, 19-30	4.8	22
238	Association Between the Decline in Muscle Health and the Decline in Bone Health in Older Individuals from the SarcoPhAge Cohort. <i>Calcified Tissue International</i> , 2019 , 104, 273-284	3.9	17
237	Coexistence of Pre-sarcopenia and Metabolic Syndrome in Arab Men. <i>Calcified Tissue International</i> , 2019 , 104, 130-136	3.9	5
236	The relationship between the dietary inflammatory index and prevalence of radiographic symptomatic osteoarthritis: data from the Osteoarthritis Initiative. <i>European Journal of Nutrition</i> , 2019 , 58, 253-260	5.2	19
235	Differentiation between various Chondroitin sulfate formulations in symptomatic knee osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, e55	2.4	1
234	Comparison of the performance of five screening methods for sarcopenia. <i>Clinical Epidemiology</i> , 2018 , 10, 71-82	5.9	59
233	Evidence for the Domains Supporting the Construct of Intrinsic Capacity. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018 , 73, 1653-1660	6.4	190
232	Sarcopenic osteoarthritis: a new entity in geriatric medicine?. <i>European Geriatric Medicine</i> , 2018 , 9, 141-148		6
231	Pitfalls in the measurement of muscle mass: a need for a reference standard. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018 , 9, 269-278	10.3	294
230	Early Clinically Relevant Improvement in Quality of Life and Clinical Outcomes 1 Year Postsurgery in Patients with Knee and Hip Joint Arthroplasties. <i>Cartilage</i> , 2018 , 9, 127-139	3	12

229	Cross-cultural adaptation and validation of the SARC-F to assess sarcopenia: methodological report from European Union Geriatric Medicine Society Sarcopenia Special Interest Group. <i>European Geriatric Medicine</i> , 2018 , 9, 23-28	3	23
228	Critical analysis of valuation and strategical orientation of merger and acquisition deals in the pharmaceutical industry. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018 , 18, 147-160 ^{2.2}		9
227	French translation and validation of the sarcopenia screening tool SARC-F. <i>European Geriatric Medicine</i> , 2018 , 9, 29-37	3	16
226	Profile of osteoarthritic patients undergoing hip or knee arthroplasty, a step toward a definition of the "need for surgery". <i>Aging Clinical and Experimental Research</i> , 2018 , 30, 315-321	4.8	13
225	Quality of life assessment in musculo-skeletal health. <i>Aging Clinical and Experimental Research</i> , 2018 , 30, 413-418	4.8	101
224	Statin use and knee osteoarthritis progression: Results from a post-hoc analysis of the SEKOIA trial. <i>Joint Bone Spine</i> , 2018 , 85, 609-614	2.9	18
223	The projected public health and economic impact of vitamin D fortified dairy products for fracture prevention in France. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018 , 18, 191-195	2.2	5
222	Nutritional Status and Nutritional Treatment Are Related to Outcomes and Mortality in Older Adults with Hip Fracture. <i>Nutrients</i> , 2018 , 10,	6.7	104
221	The Authors reply: "Dual energy X-ray absorptiometry: gold standard for muscle mass?" by Scafoglieri et al. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018 , 9, 788-790	10.3	2
220	Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). <i>Aging Clinical and Experimental Research</i> , 2018 , 30, 111-117	4.8	39
219	Quality of life in sarcopenia measured with the SarQoL [®] : impact of the use of different diagnosis definitions. <i>Aging Clinical and Experimental Research</i> , 2018 , 30, 307-313	4.8	38
218	Prediction of the Incidence of Falls and Deaths Among Elderly Nursing Home Residents: The SENIOR Study. <i>Journal of the American Medical Directors Association</i> , 2018 , 19, 18-24	5.9	37
217	The authors reply: Letter on: "Pitfalls in the measurement of muscle mass: a need for a reference standard" by Clark et al. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018 , 9, 1272-1274	10.3	6
216	Polish Validation of the SarQoL, a Quality of Life Questionnaire Specific to Sarcopenia. <i>Journal of Clinical Medicine</i> , 2018 , 7,	5.1	17
215	Plasma Klotho and Mortality Risk Among Nursing Home Residents: Results From the SENIOR Cohort. <i>Journal of the American Medical Directors Association</i> , 2018 , 19, 1139-1140	5.9	3
214	Evaluation of the Responsiveness of the SarQoL Questionnaire, a Patient-Reported Outcome Measure Specific to Sarcopenia. <i>Advances in Therapy</i> , 2018 , 35, 1842-1858	4.1	14
213	Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide. <i>Calcified Tissue International</i> , 2018 , 103, 540-545 ^{3.9}		20
212	Reliability of muscle strength measures obtained with a hand-held dynamometer in an elderly population. <i>Clinical Physiology and Functional Imaging</i> , 2017 , 37, 332-340	2.4	46

211	Relationship Between Low Bone Mineral Density and Fractures With Incident Cardiovascular Disease: A Systematic Review and Meta-Analysis. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 1126-1135	6.3	72
210	Use of Intraarticular Hyaluronic Acid in the Management of Knee Osteoarthritis in Clinical Practice. <i>Arthritis Care and Research</i> , 2017 , 69, 1287-1296	4.7	65
209	Adverse Health Events Related to Self-Medication Practices Among Elderly: A Systematic Review. <i>Drugs and Aging</i> , 2017 , 34, 359-365	4.7	21
208	Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment. <i>Rheumatology</i> , 2017 , 56, 1167-1176	3.9	21
207	Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. <i>Journal of Bone Oncology</i> , 2017 , 7, 1-12	4.5	127
206	10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 513-523	18.1	419
205	A scoping review of the public health impact of vitamin D-fortified dairy products for fracture prevention. <i>Archives of Osteoporosis</i> , 2017 , 12, 57	2.9	11
204	Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONDroitin versus CElecoxib versus Placebo Trial (CONCEPT). <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1537-1543	2.4	54
203	Vitamin D supplementation in the prevention and management of major chronic diseases not related to mineral homeostasis in adults: research for evidence and a scientific statement from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO). <i>Endocrine</i> , 2017 , 56, 245-261	4	40
202	Vitamin D status correction in Saudi Arabia: an experts' consensus under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases (ESCEO). <i>Archives of Osteoporosis</i> , 2017 , 12, 1	2.9	47
201	PRIORITIES FOR HEALTH ECONOMIC METHODOLOGICAL RESEARCH: RESULTS OF AN EXPERT CONSULTATION. <i>International Journal of Technology Assessment in Health Care</i> , 2017 , 33, 609-619	1.8	5
200	Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) confirms that abaloparatide is a valuable addition to the armamentarium against osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 1811-1813	4	6
199	Health Outcomes of Sarcopenia: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2017 , 12, e0169548	3.7	426
198	The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation. <i>Oncotarget</i> , 2017 , 8, 75646-75663	3.3	34
197	English translation and validation of the SarQoL [®] , a quality of life questionnaire specific for sarcopenia. <i>Age and Ageing</i> , 2017 , 46, 271-276	3	27
196	Self-Administration of Medicines and Dietary Supplements Among Female Amateur Runners: A Cross-Sectional Analysis. <i>Advances in Therapy</i> , 2017 , 33, 2257-2268	4.1	8
195	International endorsement of the ESCEO algorithm for management of knee osteoarthritis in clinical practice. <i>Seminars in Arthritis and Rheumatism</i> , 2017 , 47, e10	5.3	6
194	Current review of the SarQoL [®] : a health-related quality of life questionnaire specific to sarcopenia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017 , 17, 335-341	2.2	19

193	How clinical practitioners assess frailty in their daily practice: an international survey. <i>Aging Clinical and Experimental Research</i> , 2017 , 29, 905-912	4.8	34
192	Psychometric performance of the Romanian version of the SarQoL [®] , a health-related quality of life questionnaire for sarcopenia. <i>Archives of Osteoporosis</i> , 2017 , 12, 103	2.9	14
191	Micro factors bringing the pharmaceutical industry to a seismic shaking a qualitative research. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017 , 17, 267-274	2.2	1
190	Occurrence of Clinical Bone Fracture Following a Prolonged Stay in Intensive Care Unit: A Retrospective Controlled Study. <i>Calcified Tissue International</i> , 2017 , 101, 465-472	3.9	1
189	Adherence to a Mediterranean diet is associated with lower prevalence of osteoarthritis: Data from the osteoarthritis initiative. <i>Clinical Nutrition</i> , 2017 , 36, 1609-1614	5.9	41
188	Clinical settings in knee osteoarthritis: Pathophysiology guides treatment. <i>Maturitas</i> , 2017 , 96, 54-57	5	40
187	Influence of environmental factors on food intake among nursing home residents: a survey combined with a video approach. <i>Clinical Interventions in Aging</i> , 2017 , 12, 1055-1064	4	10
186	Meeting the Needs of Mothers During the Postpartum Period: Using Co-Creation Workshops to Find Technological Solutions. <i>JMIR Research Protocols</i> , 2017 , 6, e76	2	12
185	Effects of Dairy Products Consumption on Health: Benefits and Beliefs--A Commentary from the Belgian Bone Club and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. <i>Calcified Tissue International</i> , 2016 , 98, 1-17	3.9	138
184	Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Aging Clinical and Experimental Research</i> , 2016 , 28, 1-16	4.8	16
183	Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 45, S12-7	5.3	47
182	High Kellgren-Lawrence Grade and Bone Marrow Lesions Predict Worsening Rates of Radiographic Joint Space Narrowing; The SEKOIA Study. <i>Journal of Rheumatology</i> , 2016 , 43, 657-65	4.1	14
181	Optimizing the management of osteoarthritis-Transitioning evidence-based guidelines into practical guidance for real-world clinical practice. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 45, S1-2	5.3	3
180	Efficacy and safety of hyaluronic acid in the management of osteoarthritis: Evidence from real-life setting trials and surveys. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 45, S28-33	5.3	103
179	Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. <i>Drugs and Aging</i> , 2016 , 33, 75-85	4.7	68
178	A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 45, S3-11	5.3	159
177	Osteoporosis and sarcopenia: two diseases or one?. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2016 , 19, 31-6	3.8	110
176	A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes. <i>Current Medical Research and Opinion</i> , 2016 , 32, 997-1004	2.5	28

175	Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. <i>Aging Clinical and Experimental Research</i> , 2016 , 28, 47-58	4.8	69
174	The role of diet and exercise and of glucosamine sulfate in the prevention of knee osteoarthritis: Further results from the PRevention of knee Osteoarthritis in Overweight Females (PROOF) study. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 45, S42-8	5.3	19
173	Patients' Expectations Impact Their Satisfaction following Total Hip or Knee Arthroplasty. <i>PLoS ONE</i> , 2016 , 11, e0167911	3.7	66
172	Self-Medication Practice among Amateur Runners: Prevalence and Associated Factors. <i>Journal of Sports Science and Medicine</i> , 2016 , 15, 387-8	2.7	2
171	Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1268-71	2.4	17
170	Re: Kucharz EJ, Kovalenko V, Szűcs, et'al. A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes. <i>Curr Med Res Opin</i> 2016;32:997-1004. <i>Current Medical Research and Opinion</i> , 2016 , 32, 1771-1772	2.5	
169	Sarcopenia in daily practice: assessment and management. <i>BMC Geriatrics</i> , 2016 , 16, 170	4.1	270
168	Macro-economic factors influencing the architectural business model shift in the pharmaceutical industry. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016 , 16, 571-578	2.2	7
167	Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritis. <i>Drugs and Aging</i> , 2015 , 32, 179-87	4.7	64
166	Development and validation of the French version of a tool assessing patient's expectations in lower limb osteoarthritis. <i>Journal of Orthopaedics</i> , 2015 , 12, 46-57	1.6	6
165	Concordance between muscle mass assessed by bioelectrical impedance analysis and by dual energy X-ray absorptiometry: a cross-sectional study. <i>BMC Musculoskeletal Disorders</i> , 2015 , 16, 60	2.8	95
164	Burden of frailty in the elderly population: perspectives for a public health challenge. <i>Archives of Public Health</i> , 2015 , 73, 19	2.6	218
163	Development of a self-administrated quality of life questionnaire for sarcopenia in elderly subjects: the SarQoL. <i>Age and Ageing</i> , 2015 , 44, 960-6	3	60
162	A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis. <i>Pharmacoeconomics</i> , 2015 , 33, 205-24	4.4	65
161	Cost-effectiveness of vitamin D and calcium supplementation in the treatment of elderly women and men with osteoporosis. <i>European Journal of Public Health</i> , 2015 , 25, 20-5	2.1	34
160	Aesthetic discomfort in hand osteoarthritis: results from the LIège Hand Osteoarthritis Cohort (LIHOC). <i>Arthritis Research and Therapy</i> , 2015 , 17, 346	5.7	9
159	Public health impact and cost-effectiveness of dairy products supplemented with vitamin D in prevention of osteoporotic fractures. <i>Archives of Public Health</i> , 2015 , 73, 48	2.6	17
158	Clinical Trials Using Mobile Health Applications. <i>Pharmaceutical Medicine</i> , 2015 , 29, 17-25	2.3	5

157	Publication outcomes of the abstracts presented at the 2011 European Congress on Osteoporosis, Osteoarthritis and Musculo-Skeletal Diseases (ECCEO-IOF11): A position paper of the European Society for Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculo-Skeletal Diseases (ESCEO) and the International Osteoporosis and Other Skeletal Diseases Foundation (IOF). <i>Archives of Osteoporosis</i> , 2015 , 10, 11	2.9	8
156	Letter to the editor. <i>Seminars in Arthritis and Rheumatism</i> , 2015 , 44, e15	5.3	
155	Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis. <i>Current Medical Research and Opinion</i> , 2015 , 31, 1041-5	2.5	16
154	Commentary on recent therapeutic guidelines for osteoarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2015 , 44, 611-7	5.3	68
153	Mobile Phone-Connected Wearable Motion Sensors to Assess Postoperative Mobilization. <i>JMIR MHealth and UHealth</i> , 2015 , 3, e78	5.5	22
152	Patients' preferences for osteoporosis drug treatment: a discrete-choice experiment. <i>Arthritis Research and Therapy</i> , 2014 , 16, R36	5.7	36
151	Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis. <i>Rheumatology</i> , 2014 , 53, 1457-64	3.9	18
150	An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 44, 253-63	5.3	315
149	Gaucher disease and bone manifestations. <i>Calcified Tissue International</i> , 2014 , 95, 477-94	3.9	40
148	The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: a consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Maturitas</i> , 2014 , 79, 122-32	5	169
147	The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 4336-45	5.6	378
146	Challenges for the development of bone-forming agents in Europe. <i>Calcified Tissue International</i> , 2014 , 94, 469-73	3.9	16
145	Teriparatide therapy for denosumab-induced osteonecrosis of the jaw in a male osteoporotic patient. <i>Calcified Tissue International</i> , 2014 , 95, 94-6	3.9	13
144	The promise of wearable activity sensors to define patient recovery. <i>Journal of Clinical Neuroscience</i> , 2014 , 21, 1089-93	2.2	66
143	Romosozumab in postmenopausal women with low bone mineral density. <i>New England Journal of Medicine</i> , 2014 , 370, 412-20	59.2	781
142	Effects of vitamin D in the elderly population: current status and perspectives. <i>Archives of Public Health</i> , 2014 , 72, 32	2.6	43
141	Cardiac concerns associated with strontium ranelate. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 1209-13	4.1	47
140	Monitoring of osteoporosis therapy. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014 , 28, 835-41	6.5	11

139	Sarcopenia: burden and challenges for public health. <i>Archives of Public Health</i> , 2014 , 72, 45	2.6	211
138	A reference case for economic evaluations in osteoarthritis: an expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 44, 271-82	5.3	22
137	Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of the American Heart Association</i> , 2014 , 3, e000515	6	73
136	Current challenges in the treatment of osteoporosis: an opportunity for bazedoxifene. <i>Current Medical Research and Opinion</i> , 2014 , 30, 1165-76	2.5	9
135	Smart wearable body sensors for patient self-assessment and monitoring. <i>Archives of Public Health</i> , 2014 , 72, 28	2.6	251
134	Prevalence of vitamin D inadequacy in European women aged over 80 years. <i>Archives of Gerontology and Geriatrics</i> , 2014 , 59, 78-82	4	33
133	Health technology assessment in osteoporosis. <i>Calcified Tissue International</i> , 2013 , 93, 1-14	3.9	27
132	Quality of life in sarcopenia and frailty. <i>Calcified Tissue International</i> , 2013 , 93, 101-20	3.9	235
131	Health economics in the field of osteoarthritis: an expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2013 , 43, 303-13	5.3	189
130	How to define responders in osteoarthritis. <i>Current Medical Research and Opinion</i> , 2013 , 29, 719-29	2.5	60
129	Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 179-86	2.4	197
128	Risk of Hip Fracture in Community-dwelling and Institutionalized Osteoporotic Patients: A 3-year Study. <i>International Journal of Gerontology</i> , 2013 , 7, 167-170		4
127	Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 807-15	6.3	8
126	Safety concerns with the long-term management of osteoporosis. <i>Expert Opinion on Drug Safety</i> , 2013 , 12, 507-22	4.1	24
125	Strontium ranelate in the treatment of knee osteoarthritis: new insights and emerging clinical evidence. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2013 , 5, 268-76	3.8	16
124	Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids. <i>Rheumatology</i> , 2013 , 52, 1058-69	3.9	14
123	Is there potential for strontium ranelate in the management of osteoarthritis?. <i>Clinical Practice (London, England)</i> , 2013 , 10, 201-207	3	1
122	Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis. <i>Patient Preference and Adherence</i> , 2013 , 7, 133-9	2.4	66

121	Dabigatran Etexilate and Risk Of Myocardial Infarction, Major Bleeding and All-Cause Mortality: A Systematic Review and Meta-Analysis Of Randomized Controlled Trials. <i>Blood</i> , 2013 , 122, 3633-3633	2.2	
120	Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 694-701	6.3	235
119	Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. <i>Bone</i> , 2012 , 50, 289-95	4.7	48
118	Role of glucosamine in the treatment for osteoarthritis. <i>Rheumatology International</i> , 2012 , 32, 2959-67	3.6	67
117	Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial. <i>Current Medical Research and Opinion</i> , 2012 , 28, 231-9	2.5	35
116	The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. <i>Value in Health</i> , 2012 , 15, 604-12	3.3	40
115	Relationships between changes in bone mineral density or bone turnover markers and vertebral fracture incidence in patients treated with bazedoxifene. <i>Calcified Tissue International</i> , 2012 , 91, 244-9	3.9	17
114	In people with hand osteoarthritis, chondroitin sulphate therapy for 6 months improves pain and function compared with placebo. <i>Evidence-Based Medicine</i> , 2012 , 17, 152-3		4
113	Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. <i>Drugs</i> , 2011 , 71, 65-78	12.1	74
112	Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. <i>Pharmacoeconomics</i> , 2011 , 29, 895-911	4.4	51
111	Adverse drug reactions to osteoporosis treatments. <i>Expert Review of Clinical Pharmacology</i> , 2011 , 4, 593-604	3.8	31
110	Tumor-induced osteomalacia: The tumor may stay hidden!. <i>Clinical Biochemistry</i> , 2011 , 44, 1264-6	3.5	13
109	Current options for the management of postmenopausal osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 2533-52	4	23
108	Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. <i>Calcified Tissue International</i> , 2011 , 89, 91-104	3.9	138
107	Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. <i>Current Medical Research and Opinion</i> , 2011 , 27, 315-25	2.5	12
106	Cutaneous side effects of antiosteoporosis treatments. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2011 , 3, 31-41	3.8	8
105	Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. <i>Value in Health</i> , 2010 , 13, 394-401	3.3	48
104	Interest of lasofoxifene in the treatment of osteoporosis. Evaluation of "Lasofoxifene in postmenopausal women with osteoporosis". <i>N Engl J Med</i> 2010;362:686-96. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 1773-5	4	

103	Overcoming problems with adherence to osteoporosis medication. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010 , 10, 677-89	2.2	16
102	Strontium Ranelate: Long-Term Efficacy against Vertebral, Nonvertebral and Hip Fractures in Patients with Postmenopausal Osteoporosis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2010 , 2, 133-43	3.8	4
101	Strontium ranelate: a look back at its use for osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 2915-27	4	2
100	Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010 , 10, 359-66	2.2	8
99	The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. <i>Health Policy</i> , 2010 , 96, 170-7	3.2	49
98	Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years. <i>Bone</i> , 2010 , 46, 440-6	4.7	22
97	Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age. <i>Bone</i> , 2010 , 46, 1038-42	4.7	50
96	Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. <i>Bone</i> , 2010 , 47, 34-40	4.7	33
95	Oral calcitonin in the management of osteoarthritis: hope or fantasy?. <i>International Journal of Clinical Rheumatology</i> , 2010 , 5, 53-58	1.5	2
94	Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications. <i>Calcified Tissue International</i> , 2010 , 86, 202-210	3.9	70
93	Prevention and treatment of postmenopausal osteoporosis 2010 , 83-114		1
92	Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2009 , 60, 524-33		188
91	Strontium ranelate: new data on fracture prevention and mechanisms of action. <i>Current Osteoporosis Reports</i> , 2009 , 7, 96-102	5.4	6
90	Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. <i>Value in Health</i> , 2009 , 12, 687-96	3.3	57
89	Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. <i>Lancet, The</i> , 2009 , 373, 1253-63	4.0	359
88	Low dietary calcium in European postmenopausal osteoporotic women. <i>Public Health Nutrition</i> , 2009 , 12, 111-4	3.3	20
87	Highest prevalence of vitamin D inadequacy in institutionalized women compared with noninstitutionalized women: a case-control study. <i>Women's Health</i> , 2009 , 5, 49-54	3	26
86	The need for economic evaluation in osteoarthritis. <i>Aging Health</i> , 2009 , 5, 591-954		1

85	Ibandronate in the Management of Postmenopausal Osteoporosis. <i>Clinical Medicine Therapeutics</i> , 2009 , 1, CMT.S2354		
84	Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. <i>BMC Musculoskeletal Disorders</i> , 2008 , 9, 165	2.8	44
83	Bone-forming agents in the management of osteoporosis. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2008 , 22, 869-83	6.5	20
82	An Economic Evaluation of Quantitative Ultrasonometry as Pre-Screening Test for the Identification of Patients with Osteoporosis. <i>Disease Management and Health Outcomes</i> , 2008 , 16, 429-438		9
81	Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. <i>Bone</i> , 2008 , 42, 841-7	4.7	166
80	Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis. <i>Bone</i> , 2008 , 43, 343-347	4.7	48
79	Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. <i>Current Medical Research and Opinion</i> , 2008 , 24, 207-13	2.5	62
78	Ibandronate in profile: drug characteristics and clinical efficacy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008 , 4, 941-51	5.5	4
77	Low incidence of anti-osteoporosis treatment after hip fracture. <i>Journal of Bone and Joint Surgery - Series A</i> , 2008 , 90, 2142-8	5.6	112
76	Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. <i>Journal of Bone and Mineral Research</i> , 2008 , 23, 433-8	6.3	81
75	Utility values associated with osteoporotic fracture: a systematic review of the literature. <i>Calcified Tissue International</i> , 2008 , 82, 288-92	3.9	62
74	Strontium ranelate: the first agent of a new therapeutic class in osteoporosis. <i>Advances in Therapy</i> , 2008 , 25, 1235-56	4.1	28
73	Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. <i>Clinical Rheumatology</i> , 2008 , 27, 955-60	3.9	35
72	Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2008 , 58, 1687-95		211
71	Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. <i>Journal of Rheumatology</i> , 2008 , 35, 488-97	4.1	86
70	Highlights from The Seventh European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 1779-1784	4	
69	Vitamin D inadequacy in Belgian postmenopausal osteoporotic women. <i>BMC Public Health</i> , 2007 , 7, 64	4.1	24
68	Symptom and structure modifying properties of chondroitin sulfate in osteoarthritis. <i>Mini-Reviews in Medicinal Chemistry</i> , 2007 , 7, 1051-61	3.2	17

67	Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 3076-81	5.6	106
66	Injectable bisphosphonates for the treatment of osteoporosis. <i>Women's Health</i> , 2007 , 3, 719-23	3	
65	Managing the osteoporotic patient today. <i>Bone</i> , 2007 , 40, S12-S18	4.7	4
64	Calcium and vitamin D for osteoporotic fracture risk. <i>Lancet, The</i> , 2007 , 370, 632-4	4.0	12
63	Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. <i>Drugs and Aging</i> , 2007 , 24, 573-80	4.7	98
62	Intermittent bisphosphonate therapy in postmenopausal osteoporosis: progress to date. <i>Drugs and Aging</i> , 2007 , 24, 351-9	4.7	10
61	Strontium ranelate normalizes bone mineral density in osteopenic patients. <i>Aging Clinical and Experimental Research</i> , 2007 , 19, 330-3	4.8	10
60	Clinical significance of the long-term symptom-modifying effects of glucosamine sulfate: comment on the article by Brandt and Mazzuca. <i>Arthritis and Rheumatism</i> , 2006 , 54, 2339-41; author reply 2341-3		4
59	Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. <i>Arthritis and Rheumatism</i> , 2006 , 54, 1838-46		200
58	Developments in the pharmacotherapeutic management of osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 1603-15	4	24
57	The treatment of severe postmenopausal osteoporosis : a review of current and emerging therapeutic options. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2006 , 5, 15-23		10
56	Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. <i>Current Medical Research and Opinion</i> , 2006 , 22, 61-6	2.5	95
55	Intravenous ibandronate in the Treatment of Osteoporosis. <i>Drugs</i> , 2006 , 66, 1602-1603	12.1	1
54	Adherence and persistence: impact on outcomes and health care resources. <i>Bone</i> , 2006 , 38, S18-21	4.7	36
53	Osteoporosis: a still increasing prevalence. <i>Bone</i> , 2006 , 38, S4-9	4.7	586
52	Strontium ranelate: the first dual acting treatment for postmenopausal osteoporosis. <i>Clinical Orthopaedics and Related Research</i> , 2006 , 443, 55-60	2.2	22
51	Raloxifene reduces fractures in postmenopausal women with osteoporosis. <i>Clinical Orthopaedics and Related Research</i> , 2006 , 443, 48-54	2.2	19
50	Adherence to anti-osteoporotic treatment: does it really matter?. <i>Future Rheumatology</i> , 2006 , 1, 37-40		9

49	Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. <i>Journal of Bone and Mineral Research</i> , 2006 , 21, 536-42	6.3	103
48	Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. <i>Journal of Bone and Mineral Research</i> , 2006 , 21, 1113-20	6.3	147
47	A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. <i>Osteoporosis International</i> , 2006 , 17, 159-66	5.3	29
46	Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. <i>Osteoporosis International</i> , 2006 , 17, 8-19 ^{5.3}	5.3	97
45	Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. <i>Clinical Interventions in Aging</i> , 2006 , 1, 415-23	4	30
44	Assessment of structure-modifying drugs in osteoarthritis: surrogate or hard clinical end points?. <i>Future Rheumatology</i> , 2006 , 1, 199-206		
43	Direct and indirect costs attributable to osteoarthritis in active subjects. <i>Journal of Rheumatology</i> , 2006 , 33, 1152-8	4.1	52
42	The high prevalence of inadequate serum vitamin D levels and implications for bone health. <i>Current Medical Research and Opinion</i> , 2005 , 21, 579-86	2.5	78
41	Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 2301-13	4	
40	Once-Monthly Ibandronate. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2005 , 4, 389-390		
39	Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. <i>Journal of Bone and Mineral Research</i> , 2005 , 20, 1315-22	6.3	230
38	Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. <i>Osteoporosis International</i> , 2005 , 16, 239-54	5.3	52
37	Strontium ranelate: a new treatment for postmenopausal osteoporosis with a dual mode of action. <i>Current Osteoporosis Reports</i> , 2005 , 3, 30-4	5.4	19
36	Glucosamine Sulphate in Osteoarthritis: From Symptoms to Structure Modification. <i>Current Medicinal Chemistry Anti-inflammatory & Anti-allergy Agents</i> , 2005 , 4, 217-220		
35	Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 5018-24	5.6	44
34	Is there Any Interest in Combining Treatments in Osteoporosis?. <i>Current Rheumatology Reviews</i> , 2005 , 1, 49-55	1.6	4
33	Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss. <i>Journal of rheumatology Supplement, The</i> , 2005 , 76, 21-5		
32	Current concepts in the therapeutic management of osteoarthritis with glucosamine. <i>Bulletin of the Hospital for Joint Diseases</i> , 2005 , 63, 31-6		4

31	Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. <i>Archives of Internal Medicine</i> , 2004 , 164, 2024-30		225
30	Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2004 , 12, 263-8	6.2	107
29	Strontium ranelate: a new paradigm in the treatment of osteoporosis. <i>Expert Opinion on Investigational Drugs</i> , 2004 , 13, 857-64	5.9	19
28	Efficacy of alfacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. <i>Osteoporosis International</i> , 2004 , 15, 301-10	5.3	93
27	Combination/sequential therapy in osteoporosis. <i>Current Osteoporosis Reports</i> , 2004 , 2, 123-30	5.4	12
26	Age- and sex-stratified prevalence of physical disabilities and handicap in the general population. <i>Aging Clinical and Experimental Research</i> , 2004 , 16, 389-97	4.8	11
25	Evaluation of proposals of Belgian Social Security Institute for reimbursement of bone densitometry tests. Toward a cost-effective strategy for osteoporosis screening?. <i>Aging Clinical and Experimental Research</i> , 2004 , 16, 413-9	4.8	1
24	Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. <i>Journal of Bone and Mineral Research</i> , 2004 , 19, 394-401	6.3	162
23	The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. <i>New England Journal of Medicine</i> , 2004 , 350, 459-68	59.2	1239
22	Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. <i>Menopause</i> , 2004 , 11, 138-43	2.5	92
21	Combination/sequential therapy in osteoporosis. <i>Current Osteoporosis Reports</i> , 2004 , 2, 123-130	5.4	1
20	Naturocetic (glucosamine and chondroitin sulfate) compounds as structure-modifying drugs in the treatment of osteoarthritis. <i>Current Opinion in Rheumatology</i> , 2003 , 15, 651-5	5.3	18
19	Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. <i>Osteoporosis International</i> , 2003 , 14, 179-90	5.3	93
18	Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial. <i>Osteoporosis International</i> , 2003 , 14, 741-9	5.3	24
17	Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women. <i>Maturitas</i> , 2003 , 44, 259-65	5	46
16	Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. <i>Archives of Internal Medicine</i> , 2003 , 163, 1514-22		241
15	New perspectives in the management of osteoarthritis. structure modification: facts or fantasy?. <i>Journal of rheumatology Supplement, The</i> , 2003 , 67, 14-20		6
14	Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 985-92	5.6	170

13	Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002 , 87, 3609-17	5.6	415
12	Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. <i>New England Journal of Medicine</i> , 2001 , 344, 333-40	59.2	1530
11	Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. <i>New England Journal of Medicine</i> , 2001 , 344, 1434-41	59.2	3461
10	Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. <i>Lancet, The</i> , 2001 , 357, 251-6	40	906
9	Direct costs of hip fractures in patients over 60 years of age in Belgium. <i>Pharmacoeconomics</i> , 1999 , 15, 507-14	4.4	64
8	Promising new agents in osteoporosis. <i>Drugs in R and D</i> , 1999 , 1, 195-201	3.4	4
7	Increased number of hip fractures. <i>Lancet, The</i> , 1999 , 353, 2160-1	40	12
6	The use of different dual X-ray absorptiometry brands in a multicenter clinical trial: consequences and limits. <i>Journal of Clinical Densitometry</i> , 1999 , 2, 37-44	3.5	29
5	The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial. <i>Annals of Internal Medicine</i> , 1998 , 129, 1-8	8	64
4	Calcitonin for prevention and treatment of osteoporosis. <i>American Journal of Medicine</i> , 1993 , 95, 44S-47S.	4	54
3	Minimal levels of serum estradiol prevent postmenopausal bone loss. <i>Calcified Tissue International</i> , 1992 , 51, 340-3	3.9	54
2	Effect of calcitonin on bone mass and fracture rates. <i>American Journal of Medicine</i> , 1991 , 91, 19S-22S	2.4	31
1	Additive Effects of Raloxifene and Alendronate on Bone Density and Biochemical Markers of Bone Remodeling in Postmenopausal Women with Osteoporosis		76